Tengion, Inc. reported unaudited earnings results for the first quarter ended March 31, 2014. For the quarter, the company reported loss from operations of $4,409,000 against $4,143,000 for the same period a year ago. Net loss was $34,258,000 or $1.91 per share basic and diluted against $5,774,000 or $2.11 loss per share basic and diluted for the same period a year ago.

Adjusted net loss was $6,211,000 or $0.35 loss per share against $5,535,000 or $2.02 for the same period a year ago. The increase in research and development expense was primarily due to an increase in compensation and related expenses resulting from additional employees and an increased use of clinical and regulatory consultants, as well as an increase in external services related to the clinical trials for the Neo-Kidney Augment program. The increased adjusted net loss was primarily due to an increase in research and development expense of $0.3 million and an increase in interest expense of $0.5 million, offset in part by a decrease in general and administrative expense of $0.1 million.